Seung-Jung Park
83
13
17
42
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 70/100
26.5%
22 terminated/withdrawn out of 83 trials
65.6%
-20.9% vs industry average
37%
31 trials in Phase 3/4
0%
0 of 42 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (83)
(PREventive Invasive Strategy for Obstructive Coronary Artery Disease With Vulnerable Plaque Evaluated by CoroNary Computed Tomography Angiography)-2
Role: lead
Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem Lesions
Role: lead
Evaluation of Effectiveness and Safety of Hybrid Coronary Revascularization
Role: lead
Observational Study for Left Main Disease Treatment
Role: lead
Study of the Natural History of FFR Guided Percutaneous Coronary Intervention
Role: lead
IRIS-Onyx Cohort in the IRIS-DES Registry
Role: lead
Evaluation of Effectiveness and Safety of XIENCE Sierra in Routine Clinical Practice
Role: lead
Evaluation of Effectiveness and Safety of Aortic Valve Replacement in Routine Clinical Practice
Role: lead
Evaluation of Effectiveness and Safety of Rotational Atherectomy in Routine Clinical Practice
Role: lead
Asan Medical Center Myocardial Infarction Registry
Role: lead
Optical Coherence Tomography Versus Intravascular Ultrasound Guided Percutaneous Coronary Intervention
Role: lead
IRIS- DESyne X2 in the IRIS-DES Registry
Role: lead
Asan Multivessel Registry
Role: lead
Prognosis of Coronary Stenosis Based on Intracoronary Imaging; A Multicenter, Prospective Observational Study
Role: lead
Evaluation of Effectiveness and Safety of Xience Skypoint Stents in Routine Clinical Practice
Role: lead
Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)
Role: lead
The DECISION-CTO Extended 10 Y Follow-up
Role: lead
XIENCE Xpedition/Alpine/Sierra in Routine Clinical Practice
Role: lead
Fractional Flow Reserve Versus Angiography for Treatment-Decision and Evaluation of Significant Left MAIN Coronary Artery Disease
Role: lead
Drug-Eluting Balloon Registry in Routine Clinical Practice
Role: lead